VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People

Alaska Native and American Indian (AN/AI) people have unique pharmacogene variation that may affect warfarin disposition and therapeutic response. We performed targeted genotyping for cytochrome P450 (CYP)2C9, vitamin K epoxide oxidase reductase complex subunit 1 (VKORC1), CYP4F2,CYP4F11, and gamma‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Lindsay M., Robinson, Renee F., Ray, Lily, Khan, Burhan A., Li, Tianran, Dillard, Denise A., Schilling, Brian D., Mosley, Mike, Janssen, Patricia L., Fohner, Alison E., Rettie, Allan E., Thummel, Kenneth E., Thornton, Timothy A., Veenstra, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510382/
https://www.ncbi.nlm.nih.gov/pubmed/30821933
http://dx.doi.org/10.1111/cts.12611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510382/
https://www.ncbi.nlm.nih.gov/pubmed/30821933
http://dx.doi.org/10.1111/cts.12611

Ejemplares similares